Pfizer’s India managing director, S Sridhar, talks to Scrip about funding startups focused on oncology and digital health, via the CSR route. Two such startups, SiCureMi and Tinkertech, are close to commercialization. Meanwhile, Pfizer's pact with MPP will allow the COVID-19 antiviral Paxlovid to find its way to India and 94 other low- and middle-income countries
Pfizer's India Managing Director S Sridhar • Source: Pfizer Ltd
Pfizer Ltd. (India) draws on the expertise of its parent Pfizer Inc. to launch innovative drugs in India – the latter spent $13.8bn or nearly 45% of sales on research and development (R&D) during 2021.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.
